From receptor architecture to outcome maturity: a clinical framework for multiorgan incretin therapy

To propose a clinically usable framework that separates receptor architecture and metabolic potency from the maturity of patient-relevant outcome evidence for incretin-based therapies.

This Commentary draws on recent cardiovascular, kidney, heart failure, peripheral artery disease, liver, and emerging polyagonist evidence to define outcome maturity across five domains: endpoint directness and clinical relevance; study design and evidentiary confidence; comparator and population context; follow-up duration, durability, and safety; and molecule-, dose-, and indication-specific applicability.

Four qualitative states of outcome evidence are proposed: preliminary, emerging, established, and mature. These categories apply to a specific molecule, dose, indication, phenotype, and outcome question and are intentionally nonnumeric. Outcome maturity does not measure treatment-effect magnitude or comparative drug efficacy. A six-step clinical workflow links the dominant organ-risk phenotype, clinically meaningful outcome, evidence maturity, applicability, treatment sustainability, and proportionate clinical positioning.

Receptor architecture defines biological potential, whereas outcome maturity characterizes the directness, robustness, durability, and applicability of clinical evidence. Clinical positioning should remain proportional to phenotype-specific evidence and should not convert differences between nonaligned trials into cross-trial efficacy rankings.